Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany

Onkologie

Volumn 33, Issue 10, 2010, Pages 512-518

  Hofheinz, Ralf Dieter ^a   Al Batran, Salah Eddin ^b   Ridwelski, Karsten ^c   Görg, Christian ^d   Wehle, Klaus ^e   Birth, Matthias ^f   Fetscher, Sebastian ^g   Scheiber, Harald ^h   Lukan, Nadine ^a   Lordick, Florian ⁱ  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c Klinikum Magdeburg   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e Niederrheinklinik   (Germany)

^f Hanse Klinikum Stralsund   (Germany)

^g SANA KLINIKUM OFFENBACH   (Germany)

^h Klinikum Ansbach   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; Metastatic gastric cancer

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC ADENOCARCINOMA; FEMALE; GERMANY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT CARE; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; ESOPHAGEAL NEOPLASMS; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; PHYSICIAN'S PRACTICE PATTERNS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77957842953     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319699     Document Type: Article

References (17)

1. Ferlay J, Bray F, Pisani P, et al.: GLOBOCAN 2002-Cancer Incidence, Mortality and Prevalence Worldwide, version 2.0. 2004. Lyon, International Agency for Research on Cancer, 2004.
2. www.rki.de/cln-169/nn-205770/DE/Content/GBE/Gesundheitsberichterstattung/ GBEDownloadsB/KID2010,templateId=raw,property=publicationFile.pdf/KID2010.pdf.
3. Wagner AD, Grothe W, Haerting J, et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.: Phase III - study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorour-acil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
5. Lutz M, Wilke H, Wagener DJ, et al.: Weekly in-fusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II- trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemein-schaft Internistische Onkologie. J Clin Oncol 2007;25:2580-2585.
6. Kang YK, Kang WK, Shin DB, et al.: Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673.
7. Cunningham D, Starling N, Rao S, et al.: Capeciat-bine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
8. Al-Batran SE, Hartmann JT, Probst S, et al.: Phase III- trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeits-gemeinschaft für Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
9. Ajani JA, Moiseyenko VM, Tjulandin S: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3210-3216.
10. Van Cutsem E, Kang YK, Chung HC, et al.: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009;27(suppl):18s, abstr LBA4509.
11. Trumper M, Ross PJ, Cunningham D, et al.: Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 2006;42:827-834.
12. Ter-Ovanesov MD, Bang Y, Yalcin S, Roth A, Zalcberg R, Soloviev V, Mallath MK, Ecstein-Fraisse EB, Wu C: Registry of gastric cancer treatment evaluation (REGATE): Baseline characteristics of 10,299 patients from 22- countries. J Clin Oncol 2009;27(suppl):15s, abstr 4575.
13. Leithäuser M, Wilhelm S, Kahl C, Eschenburg H, Jost K, Hilgendorf I, Junghanss C, Freund M: Palliative chemotherapy for advanced and metastatic gastric cancer in the community. Onkologie 2009;32(suppl 4):abstr 136.
14. Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC: Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008;14:3165-3173.
15. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007;18:1673-1679.
16. Al-Batran SE, Hartmann JT, Hofheinz R, et al.: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II- trial of the Arbeitsgemein-schaft Internistische Onkologie. Ann Oncol 2008;19:1882-1887.
17. Al-Batran SE, Homann N, Hartmann JT, et al.: 5-Fluorouracil, leucovorin and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT 65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010;28:15s (suppl; abstr 4013).